BLN24, United States of America.
Georgetown University Hospital, United States of America.
J Subst Use Addict Treat. 2024 Jan;156:209187. doi: 10.1016/j.josat.2023.209187. Epub 2023 Oct 18.
Public stigma surrounds individuals who use medication for their recovery from a substance use disorder. However, we know little about subgroups of individuals with varying levels of perceived stigma and how these levels may be associated with physical and mental health-related quality of life (HRQOL) and social support.
We used latent class analysis to define subgroups of people aged 50-72 years of age (N = 104) who were enrolled in eight medication for opioid use disorder (MOUD) programs to explore subgroupings and correlates of group membership.
We found evidence for three distinct classes of individuals and named the classes 1) the high stigma class, 2) the embarrassed class, and 3) the low stigma class. We found that people in the high-stigma class reported more rejection, more abstinence-based support group involvement, and reduced mental HRQOL.
Results suggest reducing stigma among people on MOUD may help to boost mental HRQOL and improve social support receipt. The results are consistent with iatrogenic effects of AA/NA support groups such that these treatment modalities may increase stigma due to their focus on abstinence-only treatment for substance use disorders.
公众对使用药物治疗物质使用障碍的个体存在污名化。然而，我们对不同程度感知污名的个体亚组知之甚少，也不知道这些程度如何与身心健康相关的生活质量（HRQOL）和社会支持相关。
我们使用潜在类别分析来定义年龄在 50-72 岁之间的人群的亚组（N=104），他们参加了八项阿片类药物使用障碍（MOUD）计划，以探索群体归属的亚组和相关性。
我们发现了三类不同个体的证据，并将这些类别命名为 1）高污名类别，2）尴尬类别，和 3）低污名类别。我们发现，高污名类别中的人报告了更多的拒绝，更多的基于禁欲的支持小组参与，以及更低的心理健康 HRQOL。
结果表明，减少 MOUD 患者的污名将有助于提高心理健康 HRQOL 和改善社会支持的获得。这些结果与 AA/NA 支持小组的治疗性效应一致，即这些治疗模式可能会因专注于物质使用障碍的禁欲治疗而增加污名。
